Spironolactone While Traveling: What You Need to Know Before You Go

Print or save as PDF

What spironolactone does

Spironolactone is an aldosterone antagonist. It binds competitively at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule, so more sodium and water are excreted while potassium is retained [1]. The label's main warnings are hyperkalemia, hypotension with worsening renal function, and electrolyte and metabolic abnormalities including hyponatremia [1].

Acne is not a labeled indication. The approved uses are NYHA Class III-IV heart failure, add-on therapy for hypertension, edema in cirrhosis or nephrotic syndrome, and primary hyperaldosteronism [1]. For acne the drug is used off-label; the SAFA randomized trial used 50 mg daily for 6 weeks, then 100 mg daily through week 24 [2].

Fluid loss and blood pressure

The label's hypotension warning is specific: excessive diuresis may cause symptomatic dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking ACE inhibitors or angiotensin receptor blockers [1]. It adds that renal function can also worsen with nephrotoxic drugs such as aminoglycosides, cisplatin and NSAIDs [1].

Dizziness, lethargy, leg cramps, headache and drowsiness all appear on the label's list of reported adverse reactions [1].

Potassium

The label names the things that raise potassium risk: potassium supplements, potassium-containing salt substitutes, ACE inhibitors, angiotensin receptor blockers, NSAIDs, heparin and low molecular weight heparin, and trimethoprim [1]. Concomitant use of spironolactone with potassium supplementation or with drugs that can increase potassium may lead to severe hyperkalemia [1]. The prescribing information does not specifically address electrolyte products [1].

An older-format spironolactone tablet label is blunter: potassium supplementation, whether as medication or as a diet rich in potassium, should not ordinarily be given in association with spironolactone therapy [4].

The label says to monitor serum potassium within one week of starting or changing the dose, then regularly, with closer monitoring in renal impairment or when other potassium-raising drugs are added [1]. In healthy young women taking spironolactone for acne, abnormal potassium results were about as common as in women not taking it: 13 abnormal values out of 1802 measurements (0.72%) against a 0.76% baseline rate among 1165 comparison women, and 6 of the 13 repeats came back normal [5]. That study excluded women with heart or kidney disease and women taking drugs that act on the renin-angiotensin-aldosterone system [5]. The label's monitoring instruction still stands [1].

Time zones and dose timing

Spironolactone has a mean half-life of 1.4 hours; its active metabolites have mean half-lives of 16.5 hours for canrenone, 13.8 hours for TMS (7-alpha-thiomethylspironolactone) and 15 hours for HTMS [1].

The prescribing information does not provide a schedule for shifting doses across time zones. It says to take ALDACTONE consistently with respect to food, and food increased spironolactone bioavailability by about 95% [1]. In the study behind that figure, nine healthy volunteers took a single 200 mg dose with and without a standardized breakfast, and the parent drug's 24-hour AUC rose from 288 to 493 ng·ml-1·hr (P<0.001) [6].

Interactions named on the label

NSAIDs can reduce spironolactone's diuretic, natriuretic and antihypertensive effect [1] and are separately listed among the drugs that can increase potassium [1]. Trimethoprim is on the same potassium-raising list [1]. Spironolactone reduces the renal clearance of lithium, raising the risk of lithium toxicity, and the label says to monitor lithium levels periodically [1]. Acetylsalicylic acid may reduce spironolactone's efficacy [1], and hyperkalemic metabolic acidosis has been reported with cholestyramine [1].

Spironolactone and its metabolites interfere with digoxin radioimmunoassays and raise the apparent digoxin exposure, so the label says to use an assay that does not interact [1]. The label names no cytochrome P450 enzyme for spironolactone metabolism and lists no CYP-based interactions; its interaction section covers potassium-raising agents, lithium, NSAIDs, digoxin assays, cholestyramine, aspirin, abiraterone and mitotane [1].

Sport: prohibited at all times

Spironolactone is on the WADA 2026 Prohibited List. It sits in class S5, Diuretics and Masking Agents, alongside its metabolite canrenone, and is prohibited at all times, in and out of competition [3]. Every substance in that class is a Specified Substance, and a Therapeutic Use Exemption is needed for permitted use [3].

Pregnancy

The label says to avoid spironolactone in pregnant women or to advise a pregnant woman of the potential risk to a male fetus, because of its anti-androgenic properties and animal data: rat embryofetal studies report feminization of male fetuses and endocrine dysfunction in females exposed in utero [1]. Limited human case reports and case series did not demonstrate an association with major malformations [1].